Advertisement
DNTH vs XENE
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNTH is a Hold and XENE is a Buy.
Momentum Indicator for DNTH turns positive, indicating new upward trend
DNTH saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 98 similar instances where the indicator turned positive. In 83 of the 98 cases, the stock moved higher in the following days. The odds of a move higher are at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where DNTH's RSI Oscillator exited the oversold zone, 16 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for DNTH just turned positive on October 21, 2026. Looking at past instances where DNTH's MACD turned positive, the stock continued to rise in 36 of 43 cases over the following month. The odds of a continued upward trend are 84%.
DNTH moved above its 50-day moving average on November 11, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +8.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNTH advanced for three days, in 237 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNTH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
DNTH broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for DNTH entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 21 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. DNTH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.106) is normal, around the industry mean (3.498). P/E Ratio (-20.290) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. DNTH's P/S Ratio (2500.000) is slightly higher than the industry average of (440.869).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Momentum Indicator for XENE turns positive, indicating new upward trend
XENE saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned positive. In 69 of the 93 cases, the stock moved higher in the following days. The odds of a move higher are at 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for XENE just turned positive on October 07, 2026. Looking at past instances where XENE's MACD turned positive, the stock continued to rise in 30 of 49 cases over the following month. The odds of a continued upward trend are 61%.
XENE moved above its 50-day moving average on November 11, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where XENE advanced for three days, in 189 of 283 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for XENE moved below the 200-day moving average on October 13, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XENE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
XENE broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XENE entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. XENE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.053) is normal, around the industry mean (3.498). P/E Ratio (-8.264) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (1.930) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (588.235) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XENE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
DNTH | XENE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 30 | 45 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 21 | 82 | |
SMR RATING 1..100 | 96 | 97 | |
PRICE GROWTH RATING 1..100 | 40 | 60 | |
P/E GROWTH RATING 1..100 | 27 | 12 | |
SEASONALITY SCORE 1..100 | 90 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XENE's Valuation (76) in the Biotechnology industry is in the same range as DNTH (78) in the null industry. This means that XENE’s stock grew similarly to DNTH’s over the last 12 months.
DNTH's Profit vs Risk Rating (21) in the null industry is somewhat better than the same rating for XENE (82) in the Biotechnology industry. This means that DNTH’s stock grew somewhat faster than XENE’s over the last 12 months.
DNTH's SMR Rating (96) in the null industry is in the same range as XENE (97) in the Biotechnology industry. This means that DNTH’s stock grew similarly to XENE’s over the last 12 months.
DNTH's Price Growth Rating (40) in the null industry is in the same range as XENE (60) in the Biotechnology industry. This means that DNTH’s stock grew similarly to XENE’s over the last 12 months.
XENE's P/E Growth Rating (12) in the Biotechnology industry is in the same range as DNTH (27) in the null industry. This means that XENE’s stock grew similarly to DNTH’s over the last 12 months.
| DNTH | XENE | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 80% | 1 day ago 77% |
| Stochastic ODDS (%) | 1 day ago 88% | 1 day ago 77% |
| Momentum ODDS (%) | 1 day ago 85% | 1 day ago 74% |
| MACD ODDS (%) | 1 day ago 84% | 6 days ago 61% |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 72% |
| TrendMonth ODDS (%) | 1 day ago 82% | 1 day ago 70% |
| Advances ODDS (%) | 3 days ago 81% | 1 day ago 67% |
| Declines ODDS (%) | 10 days ago 87% | 29 days ago 68% |
| BollingerBands ODDS (%) | 1 day ago 84% | 1 day ago 71% |
| Aroon ODDS (%) | 1 day ago 89% | 1 day ago 76% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DNTH’s FA Score shows that 2 FA rating(s) are green while XENE’s FA Score has 1 green FA rating(s).
- DNTH’s FA Score: 2 green, 3 red.
- XENE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DNTH’s TA Score shows that 4 TA indicator(s) are bullish while XENE’s TA Score has 4 bullish TA indicator(s).
- DNTH’s TA Score: 4 bullish, 5 bearish.
- XENE’s TA Score: 4 bullish, 5 bearish.
Price Growth
DNTH (@Biotechnology) experienced а +7.39% price change this week, while XENE (@Biotechnology) price change was +8.27% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
DNTH is expected to report earnings on Mar 16, 2027.
XENE is expected to report earnings on Mar 04, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
DNTH and
Correlation & Price change
A.I.dvisor indicates that over the last year, DNTH has been loosely correlated with EDIT. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if DNTH jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To DNTH | 1D Price Change % | ||
|---|---|---|---|---|
| DNTH | 100% | +0.55% | ||
| EDIT - DNTH | 50% Loosely correlated | -4.99% | ||
| XNCR - DNTH | 47% Loosely correlated | +1.47% | ||
| DYN - DNTH | 47% Loosely correlated | +0.39% | ||
| PTGX - DNTH | 46% Loosely correlated | -1.03% | ||
| XENE - DNTH | 46% Loosely correlated | +1.72% | ||
More | ||||
XENE and
Correlation & Price change
A.I.dvisor indicates that over the last year, XENE has been loosely correlated with RLMD. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then RLMD could also see price increases.
| Ticker / NAME | Correlation To XENE | 1D Price Change % | ||
|---|---|---|---|---|
| XENE | 100% | +1.72% | ||
| RLMD - XENE | 49% Loosely correlated | +3.75% | ||
| DNTH - XENE | 46% Loosely correlated | +0.55% | ||
| MLTX - XENE | 44% Loosely correlated | +7.56% | ||
| DYN - XENE | 43% Loosely correlated | +0.39% | ||
| REPL - XENE | 42% Loosely correlated | -6.44% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| XOVL | 17.95 | 0.29 | +1.63% |
| Defiance Daily Target 2X Long XOVR ETF (XOVL) | |||
| DOCT | 48.18 | 0.34 | +0.70% |
| FT Vest US Equity Deep Buffer ETF - October | |||
| DES | 39.57 | 0.20 | +0.51% |
| WisdomTree U.S. SmallCap Dividend Fund (DES) | |||
| MAYZ | 35.57 | N/A | N/A |
| TrueShares Structured Outcome (May) ETF (MAYZ) | |||
| STXT | 19.17 | -0.04 | -0.21% |
| Strive Total Return Bond ETF (STXT) | |||